PHIBRO ANIMAL HEALTH CORP
Financial highlights
| Metric | FY 06/30/25 | FY 06/30/24 | FY 06/30/23 | FY 06/30/22 | FY 06/30/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.3B | $1.0B | $977.9M | $942.3M | $833.4M |
| Cost of revenue | $896.3M | $704.6M | $679.7M | $656.9M | $562.0M |
| Gross profit | $399.9M | $313.1M | $298.2M | $285.4M | $271.4M |
| Selling, general & administrative | $289.5M | $259.8M | $226.4M | $206.4M | $196.5M |
| Research and development | $23.7M | $29.2M | $24.4M | $20.8M | $17.8M |
| Operating income | $110.5M | $53.3M | $71.8M | $79.0M | $74.9M |
| Interest expense | $37.2M | $23.0M | $18.7M | $12.7M | $13.7M |
| Pretax income | $68.0M | $10.9M | $54.1M | $72.3M | $66.5M |
| Income tax expense | $19.7M | $8.5M | $21.5M | $23.2M | $12.1M |
| Net income | $48.3M | $2.4M | $32.6M | $49.2M | $54.4M |
| Balance Sheet | |||||
| Cash and equivalents | $68.0M | $70.6M | $41.3M | $74.2M | $50.2M |
| Current assets | $810.6M | $601.0M | $585.7M | $566.2M | $498.9M |
| Total assets | $1.4B | $982.2M | $971.4M | $931.7M | $841.3M |
| Current liabilities | $293.5M | $204.1M | $176.0M | $190.8M | $164.1M |
| Total liabilities | $1.1B | $725.5M | $688.9M | $669.3M | $602.8M |
| Total debt | $725.1M | $313.1M | $335.4M | $288.8M | — |
| Stockholders' equity | $285.7M | $256.6M | $282.5M | $262.4M | $238.5M |
| Cash Flow Statement | |||||
| Cash from operations | $80.1M | $87.6M | $13.3M | $31.6M | $48.3M |
| Depreciation and amortization | $45.6M | $36.2M | $34.0M | $32.7M | $31.9M |
| Stock-based compensation | $717,000 | $475,000 | — | — | $1.1M |
| Capital expenditure | $38.3M | $41.2M | $51.8M | $37.0M | $29.3M |
| Free cash flow | $41.8M | $46.4M | -$38.5M | -$5.4M | $19.0M |
| Dividends paid | $19.4M | $19.4M | $19.4M | $19.4M | $19.4M |
| Impairments | $5.3M | — | — | — | — |
Shares outstanding 40.6M · Free float 1.7%
Annual filing data through FY ended June 30, 2025; float as of July 12, 2026.